Clinical responses with T lymphocytes targeting malignancy-associated κ light chains

Journal of Clinical Investigation

Volumn 126, Issue 7, 2016, Pages 2588-2596

  Ramos, Carlos A ^a,b   Savoldo, Barbara ^a,b   Torrano, Vicky ^a   Ballard, Brandon ^a   Zhang, Huimin ^a   Dakhova, Olga ^a   Liu, Enli ^a   Carrum, George ^a,b   Kamble, Rammurti T ^a,b   Gee, Adrian P ^a   Mei, Zhuyong ^a   Wu, Meng Fen ^b   Liu, Hao ^b   Grilley, Bambi ^a,b   Rooney, Cliona M ^a,b,c   Brenner, Malcolm K ^a,b   Heslop, Helen E ^a,b   Dotti, Gianpietro ^a,b  

^a TEXAS CHILDREN S HOSPITAL   (United States)

^b BCM   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTATE AMINOTRANSFERASE; CARBOPLATIN; CARMUSTINE; CD27 ANTIGEN; CD28 ANTIGEN; CD45RA ANTIGEN; CD45RO ANTIGEN; CHEMOKINE RECEPTOR CCR7; CHIMERIC ANTIGEN RECEPTOR; CISPLATIN; CLADRIBINE; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; IFOSFAMIDE; IMMUNOGLOBULIN KAPPA CHAIN; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 7; L SELECTIN; MELPHALAN; METHYLPREDNISOLONE; PACLITAXEL; PREDNISONE; RITUXIMAB; TOPOTECAN; VINCRISTINE; CD19 ANTIGEN; CD19-SPECIFIC CHIMERIC ANTIGEN RECEPTOR; LYMPHOCYTE ANTIGEN RECEPTOR;

ADOPTIVE TRANSFER; ADULT; AGED; ANEMIA; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; B LYMPHOCYTE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CYTOKINE RELEASE SYNDROME; CYTOTOXICITY; DISEASE DURATION; DNA MODIFICATION; DRUG DOSE ESCALATION; DRUG MEGADOSE; FATIGUE; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; HYPERKALEMIA; HYPOKALEMIA; IMMUNOGLOBULIN DEFICIENCY; INFUSION THERAPY; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LEUKOPENIA; LIGHT CHAIN; LOW DRUG DOSE; LYMPHOCYTE COUNT; LYMPHOCYTE TRANSFUSION; LYMPHOCYTOPENIA; MALE; MIDDLE AGED; MINIMAL RESIDUAL DISEASE; MOLECULARLY TARGETED THERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; POLYCLONAL HYPOGAMMAGLOBULINEMIA; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT RESPONSE; TUMOR IMMUNITY; CLINICAL TRIAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEASIBILITY STUDY; IMMUNOLOGY; IMMUNOPHENOTYPING; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA, NON-HODGKIN; METABOLISM; REMISSION; RETROVIRIDAE; T LYMPHOCYTE; TREATMENT OUTCOME;

ADOPTIVE TRANSFER; ADULT; AGED; ANTIGENS, CD19; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEASIBILITY STUDIES; FEMALE; HUMANS; IMMUNOGLOBULIN KAPPA-CHAINS; IMMUNOPHENOTYPING; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; RECEPTORS, ANTIGEN, T-CELL; REMISSION INDUCTION; RETROVIRIDAE; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 84978399754     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI86000     Document Type: Article

References (29)

1. Ramos CA, Dotti G. Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy. Expert Opin Biol Ther. 2011; 11 (7):855-873.
2. Brentjens RJ, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med. 2013; 5 (177):177ra138.
3. Davila ML, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014; 6 (224):224ra225.
4. Grupp SA, et al. Chimeric antigen receptor-modi-fied T cells for acute lymphoid leukemia. N Engl J Med. 2013; 368 (16):1509-1518.
5. Maude SL, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014; 371 (16):1507-1517.
6. Lee DW, et al. T cells expressing CD19 chi-meric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2015; 385 (9967):517-528.
7. Brentjens RJ, et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood. 2011; 118 (18):4817-4828.
8. Kalos M, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med. 2011; 3 (95):95ra73.
9. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011; 365 (8):725-733.
10. Kochenderfer JN, et al. Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood. 2013; 122 (25):4129-4139.
11. Kochenderfer JN, et al. B-cell depletion and remissions of malignancy along with cytokineassociated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood. 2012; 119 (12):2709-2720.
12. Kochenderfer JN, et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an antiCD19 chimeric antigen receptor. J Clin Oncol. 2015; 33 (6):540-549.
13. Savoldo B, et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest. 2011; 121 (5):1822-1826.
14. Matsui W, et al. Characterization of clonogenic multiple myeloma cells. Blood. 2004; 103 (6):2332-2336.
15. Vera J, et al. T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells. Blood. 2006; 108 (12):3890-3897.
16. Porter DL, et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med. 2015; 7 (303):303ra139.
17. Kochenderfer JN, et al. Anti-CD19 CAR T Cells Administered after Low-Dose Chemotherapy Can Induce Remissions of ChemotherapyRefractory Diffuse Large B-Cell Lymphoma. Presented at: 56th ASH Annual Meeting and Exposition; December 6-9, 2014; San Francisco, California, USA. Abstract 550. https://ash.confex.com/ash/2014/webprogram/Paper72899.html. Accessed April 28, 2016.
18. Ninomiya S, et al. Tumor indoleamine 2, 3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs. Blood. 2015; 125 (25):3905-3916.
19. Guo B, et al. CD138-directed adoptive immunotherapy of chimeric antigen receptor (CAR)modified T cells for multiple myeloma. J Cell Immunother. 2016; 2:28-35.
20. Haso W, et al. Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. Blood. 2013; 121 (7):1165-1174.
21. Hudecek M, et al. The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity. Cancer Immunol Res. 2015; 3 (2):125-135.
22. Hombach A, Hombach AA, Abken H. Adoptive immunotherapy with genetically engineered T cells: modification of the IgG1 Fc 'spacer' domain in the extracellular moiety of chimeric antigen receptors avoids 'off-target' activation and unintended initiation of an innate immune response. Gene Ther. 2010; 17 (10):1206-1213.
23. Therasse P, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000; 92 (3):205-216.
24. Cheson BD, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007; 25 (5):579-586.
25. Cheson BD, et al. National Cancer Institutesponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996; 87 (12):4990-4997.
26. Rajkumar SV, et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011; 117 (18):4691-4695.
27. Pule MA, et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med. 2008; 14 (11):1264-1270.
28. Xu Y, et al. Closely related T-memory stem cells correlate with in vivo expansion of CAR. Blood. 2014; 123 (24):3750-3759.
29. Gerdemann U, et al. Nucleofection of DCs to generate Multivirus-specific T cells for prevention or treatment of viral infections in the immunocompromised host. Mol Ther. 2009; 17 (9):1616-1625.